Estradiol — Endogenous estrogen / sex steroid hormone
17β-Estradiol (E2) is the primary endogenous estrogen in premenopausal women, produced predominantly by ovarian granulosa cells via aromatization of testosterone. Binds estrogen receptors (ERα and ERβ) — nuclear receptors that regulate transcription of hundreds of genes across uterus, breast, bone, cardiovascular system, brain, and liver. Genomic effects (hours to days): regulates FSHR, LHR, PR, and growth factor receptor expression. Non-genomic effects (minutes): rapid membrane-initiated signaling via mER. In menopause, loss of E2 causes: vasomotor symptoms (hot flashes via hypothalamic KNDy neuron disruption), urogenital atrophy (GSM), bone loss (increased osteoclast activity), mood instability, sleep disruption, and adverse cardiovascular remodeling. Transdermal routes bypass hepatic first-pass metabolism, eliminating hepatic protein synthesis stimulation (VTE risk significantly lower vs. oral).
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Endogenous estrogen / sex steroid hormone
Mechanism of Action
17β-Estradiol (E2) is the primary endogenous estrogen in premenopausal women, produced predominantly by ovarian granulosa cells via aromatization of testosterone. Binds estrogen receptors (ERα and ERβ) — nuclear receptors that regulate transcription of hundreds of genes across uterus, breast, bone, cardiovascular system, brain, and liver. Genomic effects (hours to days): regulates FSHR, LHR, PR, and growth factor receptor expression. Non-genomic effects (minutes): rapid membrane-initiated signaling via mER. In menopause, loss of E2 causes: vasomotor symptoms (hot flashes via hypothalamic KNDy neuron disruption), urogenital atrophy (GSM), bone loss (increased osteoclast activity), mood instability, sleep disruption, and adverse cardiovascular remodeling. Transdermal routes bypass hepatic first-pass metabolism, eliminating hepatic protein synthesis stimulation (VTE risk significantly lower vs. oral).
Regulatory Status
FDA-approved for multiple indications: vasomotor symptoms, vulvar/vaginal atrophy, osteoporosis prevention, female hypogonadism, primary ovarian insufficiency.
Evidence Level
Very High — WHI (n=16,608), ESTHER, E3N, SWAN cohort. NAMS 2022 position statement and IMS guidelines strongly support use within 10 years of menopause ('timing hypothesis').